Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation, potential implications for COX-2 inhibition

Recent increased adverse cardiovascular events observed with selective cyclooxygenase-2 (COX-2) inhibition led to the withdrawal of rofecoxib (Vioxx) and valdecoxib (Bextra), but the mechanisms underlying these atherothrombotic events remain unclear. Prostacyclin is the major endproduct of COX-2 in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Arehart, Eric, Stitham, Jeremiah, Asselbergs, Folkert W., Douville, Karen, MacKenzie, Todd, Fetalvero, Kristina M., Gleim, Scott, Kasza, Zsolt, Rao, Yamini, Martel, Laurie, Segel, Sharon, Robb, John, Kaplan, Aaron, Simons, Michael, Powell, Richard J., Moore, Jason H., Rimm, Eric B., Martin, Kathleen A., Hwa, John
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2008
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2793685/
https://ncbi.nlm.nih.gov/pubmed/18323528
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.107.165936
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi